These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9204086)

  • 21. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life.
    Grosshans E; Marks R; Mascaro JM; Torras H; Meynadier J; Alirezai M; Finlay AY; Soto P; Poncet M; Verschoore M; Clucas A
    Br J Dermatol; 1998 Oct; 139 Suppl 52():26-33. PubMed ID: 9990418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents.
    Brand B; Gilbert R; Baker MD; Poncet M; Greenspan A; Georgeian K; Soloff AM
    J Am Acad Dermatol; 2003 Sep; 49(3 Suppl):S227-32. PubMed ID: 12963899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical tretinoin or adapalene in acne vulgaris: an overview.
    Jain S
    J Dermatolog Treat; 2004 Jul; 15(4):200-7. PubMed ID: 15764031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adapalene 0.1% gel and adapalene 0.1% cream stimulate retinoic acid receptor mediated gene transcription without significant irritative effects in the skin of healthy human volunteers.
    Griffiths CE; Ancian P; Humphries J; Poncet M; Rizova E; Michel S; Clucas A
    Br J Dermatol; 1998 Oct; 139 Suppl 52():12-6. PubMed ID: 9990415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skin distribution and pharmaceutical aspects of adapalene gel.
    Allec J; Chatelus A; Wagner N
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 2):S119-25. PubMed ID: 9204090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1% and tretinoin cream 0.05% in patients with acne vulgaris.
    Cunliffe WJ; Danby FW; Dunlap F; Gold MH; Gratton D; Greenspan A
    Eur J Dermatol; 2002; 12(4):350-4. PubMed ID: 12095880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris.
    Nyirady J; Grossman RM; Nighland M; Berger RS; Jorizzo JL; Kim YH; Martin AG; Pandya AG; Schulz KK; Strauss JS
    J Dermatolog Treat; 2001 Sep; 12(3):149-57. PubMed ID: 12243706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative irritancy study among retinoid creams and gels.
    Toole JW; Lockhart L; Potrebka J; Bowman JP; Novack GD
    J Cutan Med Surg; 1999 Oct; 3(6):298-301. PubMed ID: 10575158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adapalene 0.1% gel has low skin irritation potential even when applied immediately after washing.
    Dunlap FE; Baker MD; Plott RT; Verschoore M
    Br J Dermatol; 1998 Oct; 139 Suppl 52():23-5. PubMed ID: 9990417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new concept of drug delivery for acne.
    Shroot B; Michel S; Allec J; Chatelus A; Wagner N
    Dermatology; 1998; 196(1):165-70. PubMed ID: 9557255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tretinoin microsphere 0.04% and 0.1%.
    Dosik JS; Homer K; Arsonnaud S
    Cutis; 2005 Apr; 75(4):238-43. PubMed ID: 15916222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Facial tolerability of topical retinoid therapy.
    Leyden J; Grove G; Zerweck C
    J Drugs Dermatol; 2004; 3(6):641-51. PubMed ID: 15624747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pivotal clinical trials of adapalene in the treatment of acne.
    Millikan LE
    J Eur Acad Dermatol Venereol; 2001; 15 Suppl 3():19-22. PubMed ID: 11843229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Split-face clinical and bio-instrumental comparison of 0.1% adapalene and 0.05% tretinoin in facial acne.
    Piérard-Franchimont C; Henry F; Fraiture AL; Fumal I; Piérard GE
    Dermatology; 1999; 198(2):218-22. PubMed ID: 10325486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial.
    Thiboutot D; Pariser DM; Egan N; Flores J; Herndon JH; Kanof NB; Kempers SE; Maddin S; Poulin YP; Wilson DC; Hwa J; Liu Y; Graeber M;
    J Am Acad Dermatol; 2006 Feb; 54(2):242-50. PubMed ID: 16443054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study.
    Stein Gold L; Weiss J; Rueda MJ; Liu H; Tanghetti E
    Am J Clin Dermatol; 2016 Jun; 17(3):293-303. PubMed ID: 26945741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blinded, randomized, vehicle-controlled study to access skin tolerability and efficacy of an anti-inflammatory moisturizer in treatment of acne with 0.1% adapalene gel.
    Chularojanamontri L; Tuchinda P; Kulthanan K; Varothai S; Winayanuwattikun W
    J Dermatolog Treat; 2016; 27(2):140-5. PubMed ID: 26293170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne.
    Brogden RN; Goa KE
    Drugs; 1997 Mar; 53(3):511-9. PubMed ID: 9074847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adapalene: a review of its use in the treatment of acne vulgaris.
    Waugh J; Noble S; Scott LJ
    Drugs; 2004; 64(13):1465-78. PubMed ID: 15212561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris.
    Kakita L
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 3):S51-4. PubMed ID: 10898831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.